Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New drugs trials could slash treatment times

15.02.2007
The current incidence and prevalence of tuberculosis are severely straining the capacity of some National Tuberculosis Control Programmes to successfully administer the WHO recommended standard six-month regimen.

Trials of a new drug combination to treat tuberculosis could cut the length of time patients have to take their medicine by a third.

Researchers at St George’s, University of London, hope that speeding up the treatment will help to reduce the 20 million cases of the disease that exist globally – many caused by patients abandoning their medication halfway through because of the long trek to a treatment centre or at the first signs it is working.

In the four-year trial, a high dose of antibiotic drug rifapentine and a broad-spectrum antibiotic, called moxifloxacin, will be given once a week to patients with pulmonary TB in Mozambique, Zambia, Zimbabwe and South Africa. Both rifapentine and moxifloxacin are already used in the treatment of TB, though not in combination. It is hoped that RIFAQUIN, as the new combination is called, will cut the treatment time from six to four months.

Dr. Stanley Mungofa, the Head of the Harare City Health Department, Harare, Zimbabwe, and an investigator in the RIFAQUIN trial, said: “TB treatment just like treatment for chronic diseases tends to be difficult for both the patient and the health system given the fact that when patients feel better they confuse better for cure and abandon their treatment.

“If treatment becomes shorter there is a better chance of them finishing their medication and being cured.”

The trial will start in July 2007and is being carried out by INTERTB, an international consortium of scientists coordinated by Dr Amina Jindani at St George’s, University of London. Professor Denis Mitchison, who successfully pioneered the reduction of treatment from 18 to six months, and Dr Tom Harrison are also on the St George’s INTERTB team.

Dr Jindani said: ‘The development of a new anti-tuberculosis drug could take 15 years and the cost estimated by the Stop TB partnership is almost 5 billion US dollars. By testing a new combination of drugs we already use we can cut that development time by 10 years at a far lower cost.’

The trial has already attracted grants of €4,281,991 (£2.855million) from the European & Developing Countries Clinical Trials Partnership (EDCTP) and a further £200,000 from the Wellcome Trust.

INTERTB is organising a one-day meeting to discuss the contribution of UK researchers to reduce TB treatment duration. The meeting will be held at St. George’s, University of London, on Thursday 22nd March, 2007 and will be attended by researchers in the United Kingdom as well as donor agencies, NGOs and members of the All Party Parliamentary Working Group on TB.

Tamsin Starr | alfa
Further information:
http://www.sgul.ac.uk

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>